FDA approves Merck's RAGWITEKTM as immunotherapy to treat ragweed allergic rhinitis
Merck announced the FDA has approved RAGWITEK™ Tablet for Sublingual Use (12 Amb a 1-U). RAGWITEK is an allergen extract indicated as immunotherapy for treatment of short ragweed pollen-induced allergic rhinitis. RAGWITEK is approved for use in adults 18 through 65 years of age. April 17, 2014